Clinicopathological significance of oestrogen receptor expression in non-small cell lung cancer

Objective To investigate the expression and clinicopathological significance of the oestrogen receptor (ER) in non-small cell lung cancer (NSCLC). Methods ER expression was examined by immunohistochemical staining of tumour tissue and adjacent normal lung tissue from 67 NSCLC patients. The relationships between ER expression and clinicopathological features were analysed. Results A higher percentage of NSCLC tissues (28/67, 41.79%) than adjacent normal lung tissues (10/55, 18.18%) were ER positive. ER expression correlated with tumour differentiation but not with gender, age, tumour histological type, tumour size, lymph node metastasis, or clinical TNM staging. The median survival times of patients with ER-positive (n = 28) and -negative (n = 39) tumours were 36 and 27 months, respectively. The 1-, 3-, and 5-year survival rates were higher for patients with ER-positive tumours than for patients with ER-negative tumours. Conclusion ER expression could be a useful prognostic biomarker and therapeutic target for patients with NSCLC.

[1]  Ming Yan,et al.  [Expression of ER and AR in lung cancer.]. , 2008, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[2]  M. Fishbein,et al.  Estrogen receptor signaling pathways in human non-small cell lung cancer , 2007, Steroids.

[3]  Yih-Leong Chang,et al.  Expression of the estrogen receptor β in 37 surgically treated pulmonary sclerosing hemangiomas in comparison with non-small cell lung carcinomas , 2005 .

[4]  X. Teng.  [World Health Organization classification of tumours, pathology and genetics of tumours of the lung]. , 2005, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[5]  Hideki Kawai,et al.  Estrogen Receptor α and β are Prognostic Factors in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[6]  J. Siegfried,et al.  Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. , 2005, Cancer research.

[7]  H. Kawai,et al.  Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  Yih-Leong Chang,et al.  Expression of the estrogen receptor beta in 37 surgically treated pulmonary sclerosing hemangiomas in comparison with non-small cell lung carcinomas. , 2005, Human pathology.

[9]  E. Perez,et al.  Phase I Trial of High-Dose Tamoxifen in Combination with Cisplatin in Patients with Lung Cancer and Other Advanced Malignancies , 2003, Cancer investigation.

[10]  Qiang Li,et al.  [Synergistic effect of toremifene and cisplatin on human lung cancer cell line A549]. , 2002, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[11]  A. Haugen,et al.  Expression of estrogen receptors α and β in human lung tissue and cell lines , 2002 .

[12]  J. Luketich,et al.  Human Non-Small Cell Lung Tumors and Cells Derived from Normal Lung Express Both Estrogen Receptor α and β and Show Biological Responses to Estrogen , 2002 .

[13]  J. Luketich,et al.  Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. , 2002, Cancer research.

[14]  A. Haugen,et al.  Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. , 2002, Lung cancer.

[15]  J. Gustafsson,et al.  Expression, Function, and Clinical Implications of the Estrogen Receptor β in Human Lung Cancers , 2001 .

[16]  E. Perez,et al.  Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial , 2001, Cancer Chemotherapy and Pharmacology.

[17]  J. Gustafsson,et al.  Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. , 2001, Biochemical and Biophysical Research Communications - BBRC.

[18]  L. Deng,et al.  [Expression and clinical significance of p53 protein , estrogen and progesterone receptors in non-small cell lung cancer]. , 2000, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[19]  M. Socinski,et al.  Estrogen-receptor-related protein p29 in primary nonsmall cell lung carcinoma: pathologic and prognostic correlations. , 1998, Cancer.

[20]  T. Naruke.  [Results of resected lung cancer based on the new UICC TNM classification, 5th edition]. , 1997, Gan to kagaku ryoho. Cancer & chemotherapy.

[21]  H. Hsu,et al.  Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. , 1996, Anticancer research.

[22]  R. Mentzer,et al.  Sex hormone receptors in non-small-cell lung cancer in human beings. , 1994, The Journal of thoracic and cardiovascular surgery.

[23]  C. Beattie,et al.  Steroid receptors in human lung cancer. , 1985, Cancer research.

[24]  C. Beattie,et al.  Steroid receptors in human lung cancer cytosols. , 1982, Cancer letters.

[25]  K. Olson.  A STUDY OF CERTAIN SEX FACTORS AND HORMONE TREATMENT IN BRONCHOGENIC CARCINOMA , 1955, The American journal of the medical sciences.